Preclinical Evaluation of Proteolytic Targeting of LCK as a Therapeutic Approach in T Cell Acute Lymphoblastic Leukemia

Researchers developed a series of lymphocyte-specific protein tyrosine kinase (LCK) degraders using dasatinib as an LCK ligand and phenyl-glutarimide as a cereblon-directing moiety. Their lead compound SJ11646 exhibited marked efficiency in cereblon-mediated LCK degradation in T cell acute lymphoblastic leukemia cells.